Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation
- 21 November 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (12) , 1767-1773
Abstract
Bispecific antibodies (BisAbs) are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule, however, their engineering requires genetic modification and remains time-consuming. Therefore, we used AJICAP second-generation technology, which drives the production of site-specific conjugation without genetic modification requirements, to generate BisAbs. Using haloketone chemistry as an alternative to maleimide chemistry, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant BisAbs were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that the antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated BisAbs. This novel approach introduces a fully chemical, site-specific strategy capable of producing BisAbs, heralding a new era in the field of biotherapeutics.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid TumorsBiomolecules, 2020
- Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugatesEuropean Journal of Medicinal Chemistry, 2020
- Minireview: Addressing the retro-Michael instability of maleimide bioconjugatesDrug Discovery Today: Technologies, 2018
- High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based LinkersBioconjugate Chemistry, 2018
- Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel ScaffoldsFrontiers in Immunology, 2017
- Quantitative Analysis of Ligand-EGFR Interactions: A Platform for Screening Targeting MoleculesPLOS ONE, 2015
- Quantitative Measurement of the Target-Mediated Internalization Kinetics of BiopharmaceuticalsPharmaceutical Research, 2014
- Bridging Disulfides for Stable and Defined Antibody Drug ConjugatesBioconjugate Chemistry, 2014
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- The Chemistry of α-Haloketones and Their Utility in Heterocyclic SynthesisMolecules, 2003